Orexin Receptor Modulators for the Treatment of Circadian Sleep-wake Disorders in Parkinson's Disease
Therapeutic Pipeline Program, 2015
Reset Therapeutics, Inc. (Reset) will develop a new therapy to address excessive daytime sleepiness, a common non-motor symptom in Parkinsonís disease (PD). The natural daily rhythm of wakefulness and sleepiness (circadian rhythm) is disrupted in Parkinsonís; up to half of individuals with PD regularly experience excessive daytime sleepiness and many fall asleep during the day without warning.
We believe that natural sleep/wake cycles can be restored in individuals with Parkinsonís with a treatment that improves alertness during the day and makes it easier to sleep at night.
We will develop and test compounds, called orexin receptor modulators, which enhance the activity of wake-promoting signals in our body. The compounds will first be tested in the laboratory to measure important chemical properties and to show that the compounds will be safe. Promising compounds will be evaluated in pre-clinical models to evaluate their impact on activity throughout the sleep/wake cycle.
Impact on Diagnosis/Treatment of Parkinsonís Disease:††††††††††††††
Improving alertness during the day and sleep quality at night may help improve quality of life in individuals with Parkinsonís.
Next Steps for Development:
Safety and efficacy of these†compounds will be further assessed in pre-clinical models of PD.
Vice President and Head of Drug Discovery at Reset Therapeutics, Inc.
Location: San Francisco, California, United States